Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NovoCare Pharmacy vs Signos

NovoCare Pharmacy
Graded #442

Lower grade

vs+6.199999999999996
Signos
Graded #293

Higher grade

The verdict

Signos takes it — 61.4/100 to 55.2/100.

Signos grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Signos (Signos+) is a metabolic-health platform that bundles clinician-prescribed compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor (CGM) and app — pairing the medication with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSignos +20
24
44
Dose & formulationNovoCare Pharmacy +2
66
64
Clinical oversightSignos +10
74
84
Labs & monitoringSignos +20
51
71
FulfillmentNovoCare Pharmacy +5
76
71
Contract termsNovoCare Pharmacy +35
55
20
NovoCare Pharmacy · left barSignos · right bar

The numbers

MetricNovoCare PharmacySignos
WeighScore55.2/10061.4/100
GradeCC
Scorecard rank#442#293
Semaglutide$349/mo (2.4 mg dose, brand-name)$199/mo (6-month plan, compounded)
TirzepatideNot disclosed$199/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
NovoCare Pharmacy

Graded #442 · C

Strengths

  • First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
  • $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
  • $349/mo standard self-pay is well below the ~$1,300/mo retail list price
  • Ships to all 50 states with no telehealth-platform middleman fees
  • Cold-chain logistics handled directly by Novo Nordisk

Where it loses points

  • Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
  • Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
  • No clinical support included — your own prescriber handles titration and side effects
  • Manufacturer-set pricing can change at any time
  • $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)
Signos

Graded #293 · C

Strengths

  • Bundles compounded GLP-1 (semaglutide) with an FDA-cleared CGM and app — glucose-guided weight loss, not just medication
  • Starting at $199/mo on a 6-month program, with the CGM included at no extra cost
  • Free rapid shipping; HSA/FSA eligible
  • Real-time glucose insights and app coaching to help sustain results after GLP-1

Where it loses points

  • Compounded GLP-1s are not FDA-approved finished products
  • Headline price is a 6-month-program rate, not month-to-month
  • Only semaglutide is shown in the program; tirzepatide availability is not confirmed
  • Compounding pharmacy partner and state availability are not published on the landing page

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard